Your browser doesn't support javascript.
loading
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.
Chi, K N; Beardsley, E; Eigl, B J; Venner, P; Hotte, S J; Winquist, E; Ko, Y-J; Sridhar, S S; Weber, D; Saad, F.
Afiliação
  • Chi KN; Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver. Electronic address: kchi@bccancer.bc.ca.
  • Beardsley E; Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver.
  • Eigl BJ; Department of Medical Oncology, Tom Baker Cancer Centre, Calgary.
  • Venner P; Department of Medical Oncology, Cross Cancer Institute, Edmonton.
  • Hotte SJ; Department of Medical Oncology, Juravinski Cancer Centre, Hamilton.
  • Winquist E; Department of Medical Oncology, London Health Sciences Centre, London.
  • Ko YJ; Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto.
  • Sridhar SS; Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada.
  • Weber D; Novartis Pharma AG, Basel, Switzerland.
  • Saad F; Department of Urology, University of Montreal, Montreal, Canada.
Ann Oncol ; 23(1): 53-58, 2012 Jan.
Article em En | MEDLINE | ID: mdl-21765178
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Terapia de Salvação / Epotilonas / Antineoplásicos Idioma: En Ano de publicação: 2012 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Terapia de Salvação / Epotilonas / Antineoplásicos Idioma: En Ano de publicação: 2012 Tipo de documento: Article